Intradigm Closes Series B Round

Intradigm Corp., a Palo Alto, Calif.-based developer of RNAi therapeutics, has raised $2.9 million in additional Series B funding, bringing the round total to $21.4 million. Astellas Venture Management led the tranche, with existing backer Lilly Ventures also participating. Other participants on the first tranche included Roche Venture Fund, MP Healthcare Venture Management, Frazier Healthcare Ventures, Alta Partners, MediBic Alliance Technology Fund and Novartis Venture Fund.

North AmericaUSBriefs